BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37742943)

  • 1. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
    Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
    Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.
    Hermans BCM; Derks JL; Hillen LM; van der Baan I; van den Broek EC; von der Thüsen JH; van Suylen RJ; Atmodimedjo PN; den Toom TD; Coumans-Stallinga C; Timens W; Dinjens WNM; Dubbink HJ; Speel EM; Dingemans AC;
    Int J Cancer; 2022 Mar; 150(5):802-815. PubMed ID: 34674268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
    Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
    Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.
    Saghaeiannejad Esfahani H; Vela CM; Chauhan A
    Front Oncol; 2021; 11():653153. PubMed ID: 34141612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
    Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the genomic landscape and tumor microenvironment among large cell carcinoma of the lung, large cell neuroendocrine of the lung, and small cell lung cancer.
    Li F; Yang Y; Xu Y; Li K; Song L; Xue Y; Dong D
    Medicine (Baltimore); 2023 Jan; 102(4):e32781. PubMed ID: 36705391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
    Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y
    Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
    Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
    Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
    Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
    Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.